Merck-Dynavax Vaccine On Hold
October 22, 2008 at 13:17 PM EDT
The Food and Drug Administration cited safety concerns for maintaining its hold on Dynavax Technologies Corp.'s (Nasdaq: DVAX) and Merck & Co. Inc.'s (NYSE: MRK) application to test their hepatitis B vaccine on humans. Shares of Dynavax slumped 97 cents to 26 cents while Merck stock lost 66 cents to $29.31.
